-
Mashup Score: 1FDA Grants Orphan Drug Designation to BVX001 in AML - 24 day(s) ago
BVX001 has received orphan drug designation from the FDA for the treatment of patients with acute myeloid leukemia.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1FDA Grants Orphan Drug Designation to BVX001 in AML - 25 day(s) ago
BVX001 has received orphan drug designation from the FDA for the treatment of patients with acute myeloid leukemia.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1FDA Grants Orphan Drug Designation to BVX001 in AML - 29 day(s) ago
BVX001 has received orphan drug designation from the FDA for the treatment of patients with acute myeloid leukemia.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2FDA Grants Fast Track Status to SLS009 for Relapsed/Refractory Acute Myeloid Leukemia - 4 month(s) ago
The FDA has granted fast track designation to SLS009 for use as a potential therapeutic option in patients with relapsed or refractory acute myeloid leukemia.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 1FDA Grants Fast Track Status to SLS009 for Relapsed/Refractory Acute Myeloid Leukemia - 4 month(s) ago
The FDA has granted fast track designation to SLS009 for use as a potential therapeutic option in patients with relapsed or refractory acute myeloid leukemia.
Source: www.onclive.comCategories: General Medicine News, Onc News and JournalsTweet
FDA Grants Orphan Drug Designation to BVX001 in AML. #oncology #AML https://t.co/WfAq6LH4FS